Lee Kendall H, Blaha Charles D, Garris Paul A, Mohseni Pedram, Horne April E, Bennet Kevin E, Agnesi Filippo, Bledsoe Jonathan M, Lester Deranda B, Kimble Chris, Min Hoon-Ki, Kim Young-Bo, Cho Zang-Hee
Department of Neurosurgery and Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota.
Neuromodulation. 2009 Apr;12(2):85-103. doi: 10.1111/j.1525-1403.2009.00199.x.
Deep Brain Stimulation (DBS) provides therapeutic benefit for several neuropathologies including Parkinson's disease (PD), epilepsy, chronic pain, and depression. Despite well established clinical efficacy, the mechanism(s) of DBS remains poorly understood. In this review we begin by summarizing the current understanding of the DBS mechanism. Using this knowledge as a framework, we then explore a specific hypothesis regarding DBS of the subthalamic nucleus (STN) for the treatment of PD. This hypothesis states that therapeutic benefit is provided, at least in part, by activation of surviving nigrostriatal dopaminergic neurons, subsequent striatal dopamine release, and resumption of striatal target cell control by dopamine. While highly controversial, we present preliminary data that are consistent with specific predications testing this hypothesis. We additionally propose that developing new technologies, e.g., human electrometer and closed-loop smart devices, for monitoring dopaminergic neurotransmission during STN DBS will further advance this treatment approach.
深部脑刺激(DBS)对包括帕金森病(PD)、癫痫、慢性疼痛和抑郁症在内的多种神经病理学疾病具有治疗益处。尽管DBS的临床疗效已得到充分证实,但其作用机制仍知之甚少。在本综述中,我们首先总结了目前对DBS机制的理解。以此知识为框架,我们接着探讨了关于丘脑底核(STN)的DBS治疗PD的一个特定假说。该假说认为,治疗益处至少部分是通过激活存活的黑质纹状体多巴胺能神经元、随后纹状体多巴胺释放以及多巴胺恢复对纹状体靶细胞的控制来实现的。尽管极具争议,但我们展示了与检验该假说的特定预测相一致的初步数据。我们还提议,开发新技术,如人体静电计和闭环智能设备,用于在STN DBS期间监测多巴胺能神经传递,将进一步推进这种治疗方法。